Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FDL169 Formulations in Healthy Subjects
NCT03527095Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FDL169 in cystic fibrosis (CF) (6 arms), sponsored by Flatley Discovery Lab. Primary endpoint: Relative bioavailability of FDL169 and its metabolites with different formulations at 17 weeks. Started Apr 2018; status: completed.
02
Drugs
FDL169
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03527095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527095.